Acyclovir—a review of the preclinical and early clinical data of a new antiherpes drug
D Brigden, P Fiddian, AE Rosling, T Ravenscroft - Antiviral research, 1981 - Elsevier
D Brigden, P Fiddian, AE Rosling, T Ravenscroft
Antiviral research, 1981•ElsevierA review of the literature on acyclovir (Zovirax), a new antiherpes drug, with particular activity
against herpes simplex virus types I and II and also against varicella-zoster, Epstein—Barr,
cytomegalo and herpes B viruses, is presented. The article deals with 'in vitro'and 'in
vivo'efficacy in animals, animal toxicity, latency and resistance, the mechanism of action and
early clinical experience.
against herpes simplex virus types I and II and also against varicella-zoster, Epstein—Barr,
cytomegalo and herpes B viruses, is presented. The article deals with 'in vitro'and 'in
vivo'efficacy in animals, animal toxicity, latency and resistance, the mechanism of action and
early clinical experience.
Abstract
A review of the literature on acyclovir (Zovirax), a new antiherpes drug, with particular activity against herpes simplex virus types I and II and also against varicella-zoster, Epstein—Barr, cytomegalo and herpes B viruses, is presented. The article deals with ‘in vitro’ and ‘in vivo’ efficacy in animals, animal toxicity, latency and resistance, the mechanism of action and early clinical experience.
Elsevier
